News
Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the ...
Zacks.com on MSN5h
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
Zacks Investment Research on MSN5h
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
Bristol Myers’ (BMY) is striving hard for the label expansion of its key drugs. The company’s growth portfolio comprises ...
Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback